Navigation Links
Plato BioPharma, Inc. Sponsors Novel Disease Model Award
Date:4/1/2011

WESTMINSTER, Colo., April 1, 2011 /PRNewswire/ -- Plato BioPharma, Inc. ("PBI") announced today that the company has committed to sponsor The American Physiological Society's (APS) Novel Disease Model Awards for 2011 through 2013.  Each year, the APS's Physiologists in Industry Committee selects a Predoctoral and Postdoctoral fellow at the Experimental Biology conference as award recipients based on competitive abstract submissions.

"PBI embraces sponsorship of these awards to recognize outstanding trainees participating in, and driving toward approaches to study physiological mechanisms and consequences of diseases in integrative and mechanistically novel systems," said Craig F. Plato, Ph.D., CEO and founder of PBI.  "Additionally, as PBI is a preclinical contract research organization emphasizing physiological readouts in its assessment of disease models, as well as novel and integrative approaches to evaluate potential new therapeutic approaches to modify pathophysiological derangements, the Novel Disease Model Awards are squarely aligned with our scientific and business focus.  Thus, PBI truly appreciates the impact of recognizing young and talented investigators making contributions to the study and development of preclinical models of disease that may yield new avenues in the process of drug discovery."

This year's awards will be announced at the Experimental Biology conference, which is scheduled for April 9-13, 2011 in Washington, D.C.  Craig F. Platoof, PBI, and Martin Frank, Ph.D., Executive Director of The APS, will present the Novel Disease Model awards to the recipients at the APS Business Meeting.

Founded in 2009, Plato BioPharma, Inc. is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.

CONTACT: Bob Leahy, +1-303-506-6960, for Plato BioPharma, Inc.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
7. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
9. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
10. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the ... monitor mounts ever. , “Our goal was to develop a product from the ... that we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. ...
(Date:2/10/2016)... ... 2016 , ... A new leadership team for Mid-South Youth Camp, operated by ... the announcement Monday night, Feb. 8, prior to the evening session of the university’s ... creator of GO! Camp, has been named director. Gayle McDonald, currently the assistant director ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... ... sports concussion, yet the cause of injury may be one of many possible ... advanced PT Continuing Education Course , Mastering Rehab Solutions for the ...
Breaking Medicine News(10 mins):